Abstract
Although sIL-2R level has a prognostic value in patients with diffuse large B-cell lymphoma, its clinical role in patients with follicular lymphoma has not been determined. We reviewed data on 70patients diagnosed with follicular lymphoma. Ann Arbor stage was I, II, III, and IV in 6, 9, 17, and 38patients, respectively, and grade classification according to the World Health Organization criteria was 1, 2, 3A, 3B, and not available in 28, 15, 11, 4, and 12 patients, respectively. sIL-2R at diagnosis was significantly correlated with Ann Arbor stages (P< .001), number of nodal lesions (≥ 5 or not) (P= .0050), and Follicular Lymphoma International Prognosis Index risk classification (P= .0015). Furthermore, sIL-2R regressed significantly in patients who achieved complete remission, uncertain complete remission, or partial remission (P< .001), and increased when regrowth of lymphoma was shown (P< .001). Finally, a high level of sIL-2R at diagnosis was correlated with shorter progression-free survival (P= .018) and time to next treatment (P< .001). Serum-soluble interleukin-2 receptor is correlated with tumor burden at diagnosis and during the clinical course of therapies in patients with follicular lymphoma, and our data support its usefulness to function as a surrogate marker of tumor progression.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
